PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-65.20%
Both yoy net incomes decline, with CRK at -8.65%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-5.11%
Negative yoy D&A while CRK is 2.29%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
285.96%
Some yoy growth while CRK is negative at -8.64%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
74.00%
Less working capital growth vs. CRK's 1637.69%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
74.00%
Growth of 74.00% while CRK is zero at 0.00%. Bruce Berkowitz would see a difference in minor WC usage that might affect short-term cash flow if large.
-92.71%
Negative yoy while CRK is 51.99%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-15.63%
Negative yoy CFO while CRK is 37.76%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-16.17%
Negative yoy CapEx while CRK is 11.58%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-56.74%
We reduce yoy other investing while CRK is 0.00%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
-510.35%
We reduce yoy invests while CRK stands at 11.58%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-90.48%
Negative yoy issuance while CRK is 521.98%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.